跳转至内容
Merck
CN
  • Hypericin targets osteoclast and prevents breast cancer-induced bone metastasis via NFATc1 signaling pathway.

Hypericin targets osteoclast and prevents breast cancer-induced bone metastasis via NFATc1 signaling pathway.

Oncotarget (2018-02-09)
Zhengxiao Ouyang, Xiaoning Guo, Xia Chen, Bo Liu, Qiang Zhang, Ziqing Yin, Zanjing Zhai, Xinhua Qu, Xuqiang Liu, Dan Peng, Yi Shen, Tang Liu, Qing Zhang
摘要

Bone is the most common target organ of metastasis of breast cancers. This produces considerable morbidity due to skeletal-related events, and severely reduces the quality of life. Increased osteoclast activity is implicated in breast cancer outgrowth in the bone microenvironment. Our previous observation of an anti-osteoclastic activity of hypericin, a natural plant compound, led us to investigate whether hypericin could inhibit bone metastasis and osteolysis caused by breast cancer. We find that hypericin inhibited the upregulation of osteoclasts stimulated by breast cancer cells. The activity of hypericin on osteoclasts and breast cancer-mediated osteoclastogenesis was associated with the inhibition of NFATc1 signaling pathway and attenuation of Ca

材料
产品编号
品牌
产品描述

Sigma-Aldrich
依地芬, ≥95% (HPLC)
Sigma-Aldrich
凝血酶受体激动剂, ≥97% (HPLC)